Atreca Liabilities 2024

Atreca Aktienanalyse

What does Atreca do?

Atreca Inc is a biotechnology company that specializes in researching and developing novel immunotherapies for various diseases. It was founded in 2010 by a team of renowned scientists who share a common passion for discovering innovative approaches to treating serious illnesses. The company's business model is based on the identification of antigens - biological molecules that the immune system recognizes and responds to - from the cells of patients suffering from severe diseases such as cancer or autoimmune disorders. Atreca utilizes its proprietary technology platform, called Immune Repertoire Capture (IRC) technology, to isolate and identify these antigens. Once identified, the company can use these antigens to develop new immunotherapies that activate the patient's immune system to fight the disease. These personalized immunotherapies have the potential to be more specific and effective than conventional approaches used on a broad basis. Atreca has split into two main areas to optimize its business model: monetizing research and development and making its technology platform accessible to other companies. The company's research and development department focuses on the discovery and development of personalized immunotherapies for various types of cancer and autoimmune disorders. The company recently entered into a significant milestone agreement with a subsidiary of Merck to develop personalized immunotherapies for selected types of cancer. Atreca also has a separate business unit that provides its IRC technology to other companies. This business unit offers contract research and consulting services to assist other biotechnology and pharmaceutical clients in the identification of antigens and the development of personalized immunotherapies. By providing IRC technology to other companies, Atreca has tapped into a new revenue stream that allows it to offer unique and effective biotechnology solutions in the future. In terms of its products, Atreca has several potential immunotherapy candidates in its pipeline, some of which are already being tested in clinical trials. One of its key products is a personalized immunotherapy drug called ATRC-101, which targets the treatment of patients with metastatic solid tumors. The drug utilizes Atreca's IRC technology to identify the antigens in the patients and develop personalized immunotherapies based on these antigens. Furthermore, the company has additional drug candidates in the development phase and is also considering the possibility of venturing into other disease areas such as infectious diseases. Atreca has the potential to become a key player in the biotechnology industry by providing personalized and effective immunotherapies for a variety of diseases. Atreca ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Atreca's Liabilities

Atreca's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Atreca's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Atreca's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Atreca's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Atreca’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Atreca stock

What is the level of liabilities of Atreca this year?

Atreca has a debt balance of 76.6 M USD this year.

What were the liabilities of Atreca compared to the previous year?

The liabilities of Atreca have increased by 69.84% increased compared to the previous year.

What are the consequences of high debt for investors of Atreca?

High liabilities can pose a risk for investors of Atreca, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Atreca?

Low liabilities mean that Atreca has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Atreca affect the company?

An increase in liabilities of Atreca can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Atreca affect the company?

A decrease in the liabilities of Atreca can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Atreca?

Some factors that can influence the liabilities of Atreca include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Atreca so important for investors?

The liabilities of Atreca are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Atreca take to modify the liabilities?

To change its liabilities, Atreca can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Atreca pay?

Over the past 12 months, Atreca paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Atreca is expected to pay a dividend of 0 USD.

What is the dividend yield of Atreca?

The current dividend yield of Atreca is .

When does Atreca pay dividends?

Atreca pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Atreca?

Atreca paid dividends every year for the past 0 years.

What is the dividend of Atreca?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Atreca located?

Atreca is assigned to the 'Health' sector.

Wann musste ich die Aktien von Atreca kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Atreca from 11/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did Atreca pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of Atreca in the year 2023?

In the year 2023, Atreca distributed 0 USD as dividends.

In which currency does Atreca pay out the dividend?

The dividends of Atreca are distributed in USD.